Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo

1 Feb 2004

Abstract excerpt

The tumor necrosis factor family ligand, tumor necrosis factor-related activation-induced cytokine (TRANCE), and its receptors, receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG), are known to be regulators of development and activation of osteoclasts in bone remodeling. Sustained osteoclast activation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone health and treatments
Share to Bone Metabolism and Diseases
Share to S100 Proteins and Annexins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14679212
DOI: 10.1074/jbc.m309690200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in VivoPMID 14679212Read ↗

Biology of the RANKLâ€“RANKâ€“OPG System in Immunity, Bone, and BeyondSemantic proximity Read ↗

Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling.Semantic proximity Read ↗

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.Semantic proximity Read ↗

Denosumab: mechanism of action and clinical outcomesSemantic proximity Read ↗

Role of RANKL Signaling in Bone HomeostasisSemantic proximity Read ↗

Non-pyroptotic caspase-11 activity regulates osteoclastogenesis and pathological bone lossSemantic proximity Read ↗

Historically significant events in the discovery of RANK/RANKL/OPGSemantic proximity Read ↗

RANKL and RANK in Cancer TherapySemantic proximity Read ↗

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.Semantic proximity Read ↗

RANKL/OPG; Critical role in bone physiology.Semantic proximity Read ↗

Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis.Semantic proximity Read ↗

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.